Join
Live feed
·
PRReleasevia Quantisnow
Vanda Pharmaceuticals Inc. logo

Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovation

ByQuantisnow·Wall Street's wire, on your screen.
VNDA· Vanda Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track VNDA (Vanda Pharmaceuticals Inc.) and more on Quantisnow.